GlassScriptPhysician profile
Noel E Ursua
NPI 1639166937
$4,168.72
in general payments reported to CMS, 2019-2025
26 companies · $770 in 2025
The $770 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,450 · 2023: $1,409 · 2024: $539 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,718.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $524.36 | 2023 | Spravato, Invega Trinza, Invega Sustenna |
| Abbvie INC. | $365.65 | 2022-2023 | |
| Shield Therapeutics INC | $249.50 | 2022 | |
| Novo Nordisk INC | $232.92 | 2024-2025 | Wegovy |
| Exact Sciences Corporation | $196.02 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Scynexis, INC. | $155.39 | 2022 | |
| Cvrx, INC. | $151.15 | 2022 | |
| Amgen INC. | $150.00 | 2024 | Repatha |
| Genzyme Corporation | $148.81 | 2023 | |
| Madrigal Pharmaceuticals | $142.45 | 2024 | Rezdiffra |
| Grifols USA, LLC | $137.77 | 2025 | Gamunex-C |
| Apellis Pharmaceuticals, INC. | $133.30 | 2023 | |
| Edwards Lifesciences Corporation | $131.19 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Hologic Sales and Service, LLC | $126.82 | 2023 | Aptima |
| Neurocrine Biosciences, INC. | $126.44 | 2024 | Ingrezza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.52 | 2023 | |
| Melinta Therapeutics, LLC | $121.95 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $121.63 | 2022 | |
| Horizon Therapeutics Plc | $121.55 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $119.76 | 2025 | Airsupra |
| Biogen, INC. | $114.19 | 2025 | Zurzuvae |
| Teva Pharmaceuticals USA, INC. | $103.60 | 2022 | |
| Alkermes, INC. | $99.76 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $95.26 | 2023 | Evkeeza |
| Amarin Pharma, INC. | $89.61 | 2025 | Vascepa |
| Janssen Scientific Affairs, LLC | $85.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noel Ursua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.